GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Forward PE Ratio

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Forward PE Ratio : 0.00 (As of Jun. 16, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Forward PE Ratio?

Cotinga Pharmaceuticals's Forward PE Ratio for today is 0.00.

Cotinga Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Cotinga Pharmaceuticals's PE Ratio for today is 0.00.


Cotinga Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Cotinga Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Forward PE Ratio Chart

Cotinga Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Cotinga Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Cotinga Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Forward PE Ratio falls into.



Cotinga Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Cotinga Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019